ContraFect

CFRX NASDAQ
0.4000
-0.0102
-2.49%
Opening 14:15 05/24 EDT
Open
0.4200
Prev Close
0.4102
High
0.4250
Low
0.4000
Volume
164.97K
Avg Vol (3M)
1.12M
52 Week High
2.927
52 Week Low
0.3550
% Turnover
0.21%
Market Cap
31.76M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.
MORE >

Recently

Name
Price
%Change